Atropine Sulfate
NDC Package 51662-1509-1

11-digit billing NDC: 51662150901

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Atropine Sulfate is in the treatment of parkinsonism. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1509.

Identification & Billing

NDC Package Code
51662-1509-1
Package Description
1 mL in 1 VIAL, SINGLE-DOSE
Product Code
11-Digit Billing Format
51662150901
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Atropine Sulfate
Dosage Form
-
Usage Information
In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
06-14-2021
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1509-1 identifies a specific commercial package of 1 ml in 1 vial, single-dose of Atropine Sulfate, labeled by Hf Acquisition Co Llc, Dba Healthfirst. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on June 14, 2021. The current certification is valid through December 31, 2025.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662150901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1509-1
11-Digit CMS (5-4-2)
51662-1509-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.